NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, Forecast & News

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals announced that its board has authorized a stock repurchase program on Tuesday, November 5th 2019, which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 2.9% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's management believes its shares are undervalued.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) posted its quarterly earnings data on Thursday, February, 6th. The biopharmaceutical company reported $7.50 EPS for the quarter, beating analysts' consensus estimates of $6.03 by $1.47. The biopharmaceutical company earned $2.17 billion during the quarter, compared to analysts' expectations of $2.10 billion. Regeneron Pharmaceuticals had a return on equity of 24.14% and a net margin of 26.91%. The business's quarterly revenue was up 12.6% on a year-over-year basis. During the same period last year, the company earned $6.84 earnings per share. View Regeneron Pharmaceuticals' Earnings History.

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Regeneron Pharmaceuticals.

20 equities research analysts have issued 1 year price targets for Regeneron Pharmaceuticals' shares. Their forecasts range from $320.00 to $500.00. On average, they anticipate Regeneron Pharmaceuticals' stock price to reach $409.21 in the next twelve months. This suggests that the stock has a possible downside of 8.0%. View Analyst Price Targets for Regeneron Pharmaceuticals.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 9 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regeneron Pharmaceuticals.

Press coverage about REGN stock has trended very negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,620,000 shares, an increase of 5.6% from the January 15th total of 2,480,000 shares. Based on an average daily trading volume, of 779,400 shares, the days-to-cover ratio is currently 3.4 days. Approximately 3.2% of the company's stock are short sold. View Regeneron Pharmaceuticals' Current Options Chain.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Netflix (NFLX), Gilead Sciences (GILD), Biogen (BIIB), Celgene (CELG), Alibaba Group (BABA), NVIDIA (NVDA), Tesla (TSLA), Amgen (AMGN), Broadcom (AVGO) and Alphabet (GOOG).

Regeneron Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Capital World Investors (7.57%), Loomis Sayles & Co. L P (3.36%), State Street Corp (3.26%), FMR LLC (2.94%), Alliancebernstein L.P. (1.77%) and Polen Capital Management LLC (1.53%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Parnassus Investments CA, Janus Henderson Group PLC, Alliancebernstein L.P., Renaissance Technologies LLC, Rockefeller Capital Management L.P., Sustainable Growth Advisers LP, Pictet Asset Management Ltd. and Russell Investments Group Ltd.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.

REGN stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, LSV Asset Management, Capital World Investors, Krensavage Asset Management LLC, Skandinaviska Enskilda Banken AB publ , Loomis Sayles & Co. L P, Amundi Pioneer Asset Management Inc. and Sofinnova Investments Inc.. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $444.74.

Regeneron Pharmaceuticals has a market capitalization of $48.93 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe.View Additional Information About Regeneron Pharmaceuticals.

The official website for Regeneron Pharmaceuticals is http://www.regeneron.com/.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]